GCG and liver disorder: More specific and novel molecular targets of alpinetin in hepatic disorders therapy are required to be illustrated in further experiments, such as glucagon-like peptide-1 (GLP-1) (Milani et al., 2019), Sirtuin 1 (SIRT1) (Farghali et al., 2019), Yes-associated protein (YAP) (Xie et al., 2021), etc.